The Current Situation: Erlotinib (Tarceva®) and Gefitinib (Iressa®) in Non-Small Cell Lung Cancer
- 1 August 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 10 (7) , 467-470
- https://doi.org/10.1634/theoncologist.10-7-467
Abstract
The Oncologist is a journal devoted to medical and practice issues for surgical, radiation, and medical oncologists.This publication has 12 references indexed in Scilit:
- FDA Drug Approval Summary: Erlotinib (Tarceva®) TabletsThe Oncologist, 2005
- Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimensLung Cancer, 2005
- Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by ImmunohistochemistryJournal of Clinical Oncology, 2005
- Tarceva (erlotinib)PharmaDeals Review, 2005
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancerEuropean Journal Of Cancer, 1996